Company profile
ENTERA BIO LTD.
NASDAQ:ENTXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TERIPARATIDE | phase1 | — | 32 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02152228 | phase2 | completed | 2014-07-01 | 2015-06-01 | Entera Bio Ltd. | A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism |
| NCT04003467 | phase2 | completed | 2019-06-30 | 2021-04-27 | Entera Bio Ltd. | A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass |
| NCT02571140 | phase1 | completed | 2013-10-01 | 2017-08-01 | Entera Bio Ltd. | A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects |
| NCT02202603 | phase1 | completed | 2011-07-01 | 2013-08-01 | Entera Bio Ltd. | A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects |
| NCT05965167 | phase1 | completed | 2023-05-11 | 2026-02-08 | Entera Bio Ltd. | Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo |
FDA applications (0)
No records yet.